The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 
By Peter Nelson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account